Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Cash from Financing Activities (2020 - 2025)

Historic Cash from Financing Activities for Rani Therapeutics Holdings (RANI) over the last 6 years, with Q3 2025 value amounting to -$1.0 million.

  • Rani Therapeutics Holdings' Cash from Financing Activities fell 11309.71% to -$1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year decrease of 8676.51%. This contributed to the annual value of $13.6 million for FY2024, which is 573047.21% up from last year.
  • Latest data reveals that Rani Therapeutics Holdings reported Cash from Financing Activities of -$1.0 million as of Q3 2025, which was down 11309.71% from $188000.0 recorded in Q2 2025.
  • In the past 5 years, Rani Therapeutics Holdings' Cash from Financing Activities ranged from a high of $71.5 million in Q3 2021 and a low of -$3.7 million during Q1 2025
  • Over the past 5 years, Rani Therapeutics Holdings' median Cash from Financing Activities value was $108500.0 (recorded in 2023), while the average stood at $6.4 million.
  • As far as peak fluctuations go, Rani Therapeutics Holdings' Cash from Financing Activities skyrocketed by 1562244.9% in 2024, and later plummeted by 318347.11% in 2025.
  • Quarter analysis of 5 years shows Rani Therapeutics Holdings' Cash from Financing Activities stood at -$570000.0 in 2021, then soared by 2709.47% to $14.9 million in 2022, then plummeted by 99.35% to $96000.0 in 2023, then surged by 5753.12% to $5.6 million in 2024, then tumbled by 117.96% to -$1.0 million in 2025.
  • Its Cash from Financing Activities was -$1.0 million in Q3 2025, compared to $188000.0 in Q2 2025 and -$3.7 million in Q1 2025.